by MS. Alcohol misuse may lead to decreased adherence to medical treatment 7 , which will also negatively affect the course of MS. Furthermore, alcohol consumption has been shown to have an inverse dose-dependent association with the risk of men and women developing MS 8 . Data on alcohol and drug use among MS patients are rather limited. A survey in the US database NARCOMS identified that, among nearly 9,000 patients, there was a high prevalence of adverse health behaviour 9 . This included smoking, high-risk alcohol intake, obesity and a sedentary lifestyle. In the few papers addressing the prevalence of alcohol misuse in MS cases, consistent values between 14% and 22% have been reported 10, 11, 12, 13 . Despite the different methods used by these authors, the values are similar and, although high, they are not necessarily different from those of the general population 14 . As for drug use among MS patients, the data are even more sparse, except with regard to cannabis with medicinal purposes 13 . The present study addresses the issue of excessive drinking and potential drug use among MS patients, using a case-control method to correct for population factors and cultural behaviour.
method
This study was approved by the Ethics Committee of Universidade Metropolitana de Santos, SP, Brazil, under the registration number CAAE 37491014.5.0000.5509, in 2014. Patients with MS attending outpatients consultations were invited to participate in this study in six MS units in Brazil. Control subjects matched for age, gender and socioeconomic status were included for each patient entering the trial. Control subjects were obtained from accompanying carers of patients attending the outpatients service due to other diseases (not MS). These control subjects referred to be in good health and not undergoing any treatment for chronic illnesses. Socioeconomic level was assessed according to the Brazilian Institute of Geography and Statistics (IBGE), which provides a scale varying from A1 to E in decreasing order of goods and possessions. All participants lived between latitude 18º 55' 07" S and 27º 35' 48" and longitude 46º 20' 01" W and 49° 03' 57" W. The study design was case-control and cross-sectional.
Each participant was individually interviewed using a set of questionnaires that investigated demographic data and also disease condition for those with MS. All participants were then screened for mood disorders using the Hospital Anxiety and Depression Scale (HAD) 15 . The consumption of alcohol was established using the Alcohol Use Disorder Identification Test (AUDIT scale) 16 . The patients' neurological disability was assessed using the expanded disability scale score (EDSS) 17 . A brief description of the scales used for assessment in the present study is presented:
• HAD: This is a 14 item scale that scores 0 to 3 points for each item. There are seven items for depression and seven for anxiety and they are presented in a mixed format, i.e., items of depression alternating with items of anxiety. This scale does not allow for diagnoses of anxiety or depression, but it serves as a screening method for population studies.
• AUDIT: The questions are related to the alcohol consumption in the past 12 months. There are 10 questions that score zero to four points, and the higher the consumption of alcohol (and its consequences), the higher is the score value.
• EDSS: This is a disability scale, scoring from zero (normal) to 10 (death by the disease). It progresses with half points, and despite overvaluing gait and ambulation, it is the most used scale to assess MS disability. Separate and direct questions regarding smoking (past or present) were also included at the end of the interview.
Statistical analysis on the data was carried out using GraphPad Prism. Two-way and one-way ANOVA, Spearman correlation, Kruskal-Wallis test, Mann-Whitney test and Student's t-test were used to analyse the results. Significant values were those with p < 0.05. All data were blindly analysed by one of the authors who was not involved with any other stage of the project.
results
Data were collected from 168 patients with MS and 168 control subjects of the same gender and similar age, city, and socioeconomic level. There were no significant differences between these groups. In summary, there were 57 males and 111 females, with a median age of 37 years in each group. The median score for the socioeconomic level was 25 for both groups. The classification system for socioeconomic level ranged from A1 (highest, 46 to 48 points) to E (lowest, zero to 7 points). A score of 25 represented the middle class B2.
Among the patients, there were 156 cases of relapsing-remitting MS (RRMS), nine cases of secondary progressive MS with relapses (SPMS) and three cases of primary progressive MS (PPMS). Only two patients were not using disease-modifying drugs (DMD). Seventy-four patients had not had any changes to their DMD, while 94 had undergone at least one change to their DMD. The average disease duration was 6.5 ± 4.6 years (range 1-30 years, median 5 years). The average EDSS was 1.3 ± 1.4 (range zero to 6.5).
There were 56 patients using glatiramer acetate (Copaxone®), 65 using interferon beta (23 Avonex®, 33 Rebif® and nine Betaferon®), 22 using natalizumab (Tysabri®) and 12 using fingolimod (Gilenya®).
Patients with MS presented higher levels of depression (p = 0.001) than did controls. The same was not found for anxiety (p = 0.1).
There were no significant differences in the use of tobacco between patients with MS and controls. However, when the use of alcohol was assessed, control subjects scored significantly higher values on the AUDIT scale (p = 0.0001) than did patients with MS.
Fifty-five percent of the patients with MS scored zero on AUDIT (no use of alcohol at all), and only 3% scored seven or more points, which represents a strong likelihood of hazardous or harmful alcohol consumption. On the other hand, only 28% of the control subjects scored zero on AUDIT and 4.8%
Regarding smoking, 23.3% of control subjects had a past or present history of cigarette smoking, with an average of 12 cigarettes per day. Patients with MS had a similar past or present history of cigarette smoking (24.5%), but an average of only five cigarettes per day.
When subgroups of patients and controls were analysed, higher prevalence of alcohol intake was observed in those with anxiety in both groups alike (p = 0.03). There was no influence from age or gender on the use of alcohol, tobacco or illicit drugs in either of the groups. The presence of depression was correlated with higher use of alcohol (p = 0.04) among the control subjects, but this was not found among the patients. Patients with MS and higher disability levels, as measured using EDSS, made significantly less use of alcohol (p = 0.01). Patients with higher disability had more depression than did patients with lower levels of EDSS values (p = 0.003). No specific DMD was correlated with higher use of alcohol or tobacco. Changes to DMD (which might be considered indicative of greater difficulty in achieving disease control) were not associated with the intake of alcohol or tobacco. Age, gender and socioeconomic level were not correlated to alcohol intake or smoking for patients with MS or for control subjects. 
discussion
The present study did not confirm the findings of misuse of alcohol or tobacco by patients with MS. In fact, the control subjects made higher use of alcohol than did the patients and, when asked about alcohol during our interviews, many patients mentioned that "you are not supposed to drink if you have MS". Our results are completely different from those found in the USA 10, 12, 13 and Australia
18
, but our method was also different. While those studies comprised survey questionnaires sent to large populations of patients with MS, ours was a case-control study with individual interviews. It might be argued that patients could be inhibited from talking freely about unhealthy behavioural patterns during an interview but, in fact, their use of alcohol, drugs and smoking were already written in their medical records. The information was just confirmed and quantified during the interviews. A study on patients with MS in Canada 11 who were individually interviewed also showed high alcohol intake, but that was not a case-control study. The number of patients involved in the studies was also different. In addition, it is possible that the recommendation to avoid alcohol intake while undergoing medical treatment might have positively influenced the health habits of the patients.
The patients with MS in the present study were mostly women, had low levels of disability, were relatively young and typically were not depressed. Relapsing-remitting MS was very frequent in this population of patients, the progressive forms of MS being under-represented in our study. This is a typical finding in an outpatient environment, when patients with MS go for consultations and prescriptions on a regular basis. Those who are more limited or have progressive disease usually do not attend consultations and prefer homecare. Although these facts might have altered the results, no relationships were found between gender, disability, age, depression and alcohol consumption. The only significant factor related to alcohol intake was the presence of anxiety, but this was not different between patients and controls. It is a well-known fact that anxiety and alcohol-related disorders are comorbidities 19, 20 and this might explain the findings of the present study. 
